CAS: 26159-34-2; Sodium (S)-2-(6-Methoxynaphthalen-2-yl)Propanoate

该化合物是环烷烃的一种钠盐形式,是一种非类固抗炎药物,通常用于缓解疼痛,炎症和发烧,其特点是能够抑制环氧酶(COX),在合成丙烯菊酯,发炎和疼痛中起着关键作用;该物质似乎是白色的,白色的晶状粉,在水中溶解,适合口服和注射配方.纳普罗森钠的半衰期相对较长,允许在治疗用途中每天两次使用,经常被用来治疗节炎,月经疼痛和其他肌肉骨骼紊乱等症状.尽管一般都很好地燃烧,但可造成副作用,包括胃肠不适,心血管风险和潜在的肾脏影响,特别是长期使用.与所有药物一样,在医疗监督下,必须使用环氧钠来降低风险,并确保适当使用.

结构式图片

相似化合物

22204-53-1 23981-80-8 23979-41-1

欧盟法规

C&L通报REACH预注册

上下游产品

CAS号22204-53-1 萘普生 | CAS号23981-80-8 2-(6-甲氧基-2-萘基)丙酸 | CAS号163133-43-5 (S)-2-(6-甲氧基-2-...

合成工艺路线路线简述

  • 合成目标产物 Naproxen Sodium 主要起始原料 Naproxen
  • (文献来源)合成步骤主要原料 Naproxen
2-(6-Methoxynaphthyl)Propionaldoxime 反应生成萘普生钠
参考文献:Nitric Esters Having Anti-Inflammatory And/or Analgesic Activity And
标题:Nitric Esters Having Anti-Inflammatory And/or Analgesic Activity And
摘要:本发明涉及丙酸衍生物的硝酸酯,包括1-(对氯苯甲酰)-5-甲氧基-2-甲基-3-吲哚乙酸,5-苯甲酰-1,2-二氢-3H-吡咯并[1,2-A]吡咯-1-羧酸,6-甲氧基-2-萘乙酸等,其特征在于它们具有以下通式:##str1## 这些硝酸酯衍生物可以制成药物组合物,用于治疗其抗炎和/或镇痛活性.

海关参考信息

专利信息


专利号:WO-2017100796-A1
优先权日:2015-12-11
标 题 :Modulation of globoseries glycosphingolipid synthesis and cancer biomarkers
发明人:WONG CHI-HUEY; HSU TSUI-LING; WU CHUNG-YI; CHEUNG SARAH K C; CHUANG PO-KAI
权利人:SINACA ACAD; WONG CHI-HUEY; HSU TSUI-LING
摘要:The present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid SSEA-3/SSEA-4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta- 4GalNAcT-I; or beta-3GalT-V enzymes in the globoseries synthetic pathway. Additionally, the present disclosure is also directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA-3/SSEA-4/GLOBO H associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globoseries glycosphingolipid synthesis. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions. Furthermore, the instant disclosure also relates to cancer stem cell biomarkers for disgnostic and therapeutic uses.

专利号:US-2017283878-A1
优先权日:2015-12-11
标题:Modulation of globoseries glycosphingolipid synthesis and cancer biomarkers
发明人:WONG CHI-HUEY; WU CHUNG-YI; CHEUNG SARAH K C; CHUANG PO-KAI; HSU TSUI-LING
权利人:ACADEMIA SINICA
摘要:The present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid SSEA-3/SSEA-4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta-4GalNAcT-I; or beta-3GalT-V enzymes in the globoseries synthetic pathway. Additionally, the present disclosure is also directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA-3/SSEA-4/GLOBO H associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globoseries glycosphingolipid synthesis. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions. Furthermore, the instant disclosure also relates to cancer stem cell biomarkers for diagnostic and therapeutic uses.

专利号:US-8304409-B2
优先权日:2002-07-03
标 题:Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
发明人:EARL RICHARD A; EZAWA MAIKO; FANG XINQIN; GARVEY DAVID S; GASTON RICKY D; KHANAPURE SUBHASH P; LETTS L GORDON; LIN CHIA-EN; RANATUNGE RAMANI R; RICHARDSON STEWART K; SCHROEDER JOSEPH D; STEVENSON CHERI A; WEY SHIOW-JYI
权利人:EARL RICHARD A; EZAWA MAIKO; FANG XINQIN; GARVEY DAVID S; GASTON RICKY D; KHANAPURE SUBHASH P; LETTS L GORDON; LIN CHIA-EN; RANATUNGE RAMANI R; RICHARDSON STEWART K; SCHROEDER JOSEPH D; STEVENSON CHERI A; WEY SHIOW-JYI; NICOX SA
摘要:The invention describes novel nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated NSAID, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated NSAID, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders.

专利号:US-11639326-B2
优先权日:2017-04-06
标 题 :Continuous flow synthesis of ibuprofen
发明人:COLLINS NATHAN; MALERICH JEREMIAH; SZETO JUDY; KOZOCAS JOSEPH A
权利人:STANFORD RES INST INT
摘要:This disclosure generally relates to methods of making ibuprofen, naproxen, and derivatives thereof. This disclosure also generally relates to compounds made by the disclosed methods. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

专利号:US-9051302-B2
优先权日:2008-01-15
标 题 :Synthesis of resorcylic acid lactones useful as therapeutic agents
发明人:WINSSINGER NICOLAS; BARLUENGA SOFIA; KARPLUS MARTIN
权利人:WINSSINGER NICOLAS; BARLUENGA SOFIA; KARPLUS MARTIN; UNIV STRASBOURG
摘要:Disclosed are macrocyclic compounds of formulae I, I′, II, II′, III, III′, IV, and V, which are analogs of the pochonin resorcylic acid lactones, pharmaceutical compositions comprising the compounds, and methods and uses comprising the compounds for the treatment of diseases mediated by kinases and Heat Shock Protein 90 HSP90.

专利号:US-2013035307-A1
优先权日:2010-01-26
标 题:Methods for treating or preventing the spread of cancer using semi-synthetic glycosaminoglycosan ethers
发明人:PRESTWICH GLENN D; KENNEDY THOMAS P
权利人:UNIV UTAH RES FOUND; PRESTWICH GLENN D; KENNEDY THOMAS P
摘要:Described herein are methods for the treatment and prevention of tumor metastasis using alkylated and fluoroalkylated semi-synthetic glycosaminoglycan ethers (“SAGEsâ€?). The synthesis of sulfated alkylated and fluoroalkylated SAGEs is also described.
湖北恒硕化工有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.hengshuochem.com
企业联系电话:027-82200625;82830253👤
📞湖北恒硕化工有限公司 ⚠️参考联系方式
联系人:王硕 徐文琪
电话:027-82200625;82830253
手机:13986271535;13995541600
传真:027-82830253
邮箱:hengshuochem@163.com
通信地址: 湖北省武汉市临空港经济技术开发区碧水大道7号飘轩工业园
邮编: 430014
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

地址:湖北省武汉市临空港经济技术开发区碧水大道7号飘轩工业园
⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
江苏恩华药业股份有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.nhwa-group.com
电话: 0516-83827110👤
📞江苏恩华药业股份有限公司 ⚠️参考联系方式

销售电话:0516-83827110
邮箱:nhwa@nhwa-group.com
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
武汉华玖医药科技有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.whhjpharm.com
企业联系电话:18120446293👤
📞武汉华玖医药科技有限公司 ⚠️参考联系方式
联系人:汪经理
电话:18120446293
手机:18120446293
传真:027-59220200
邮箱:3504472216@qq.com
通信地址: 武汉市东西湖区泾河办事处陈家岭189号
邮编: 432000
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

地址:武汉市东西湖区泾河办事处陈家岭189号
⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
浙江车头制药股份有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.charioteer.cn
企业联系电话:021-68471401,68471082,68471083👤
📞浙江车头制药股份有限公司 ⚠️参考联系方式

电话:021-68471401,68471082,68471083

传真:021-68471324
邮箱:marketing@charioteer.cn
通信地址: 浙江仙居大战桐员溪
邮编:
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

地址:浙江仙居大战桐员溪
⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
湖北威德利化学科技有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.widelychemical.com
企业联系电话:13385289472👤
📞湖北威德利化学科技有限公司 ⚠️参考联系方式
联系人:赵方
电话:13385289472
手机:13385289472
传真:027- 59222918
邮箱:z13385289472@163.com
通信地址: 湖北省武汉市硚口区解放大道204号
邮编: 430033
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

地址:湖北省武汉市硚口区解放大道204号
⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
第 1 / 1 页
现货

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: Acosta-Vélez GF, Zhu TZ, Linsley CS, Wu BM. Photocurable Poly(ethylene glycol) as a Bioink for the Inkjet 3D Pharming of Hydrophobic Drugs. Int J Pharm. 2018 Apr 26. pii: S0378-5173(18)30284-9. doi: 10.1016/j.ijpharm.2018.04.056. [Epub ahead of print] pii: E1000. doi: 10.3390/molecules23051000. doi: 10.5435/JAAOS-D-17-00318. doi: 10.1038/s41598-018-24548-z.
7: Dubreuil M, Louie-Gao Q, Peloquin CE, Choi HK, Zhang Y, Neogi T. Risk of myocardial infarction with use of selected non-steroidal anti-inflammatory drugs in patients with spondyloarthritis and osteoarthritis. Ann Rheum Dis. 2018 Apr 19. pii: annrheumdis-2018-213089. doi: 10.1136/annrheumdis-2018-213089. [Epub ahead of print] doi: 10.1016/j.jacc.2018.02.036. doi: 10.1371/journal.pone.0195521. eCollection 2018. Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial. Aliment Pharmacol Ther. 2018 Apr 17. doi: 10.1111/apt.14610. [Epub ahead of print] doi: 10.1016/j.biopha.2018.04.041. [Epub ahead of print] doi: 10.1098/rsos.171814. eCollection 2018 Mar.
13: Kwak K, Ji K, Kho Y, Kim P, Lee J, Ryu J, Choi K. Chronic toxicity and endocrine disruption of naproxen in freshwater waterfleas and fish, and steroidogenic alteration using H295R cell assay. Chemosphere. 2018 Apr 7;204:156-162. doi: 10.1016/j.chemosphere.2018.04.035. [Epub ahead of print] doi: 10.1134/S0006297918020049. doi: 10.1186/s12913-018-3043-8.

合成参考文献


摘要:American Journal of Diseases of Children., 142(524), 1988 []
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知